|
Apr 30
|
Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery
|
|
Apr 25
|
Addex Reports Full Year 2024 Financial Results and Provides Corporate Update
|
|
May 8
|
Addex to Present at Bio€quity Europe 2024
|
|
Jan 9
|
Addex to Present at the Swiss Equities Baader Conference
|
|
Dec 20
|
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
|
|
Nov 29
|
Addex Reports Q3 2023 Financial Results and Provides Corporate Update
|
|
Nov 28
|
Addex Convenes Extraordinary General Meeting
|
|
Oct 6
|
Addex Announces Plan to Implement ADS Ratio Change
|
|
Oct 5
|
Addex Therapeutics focused on securing new partnerships to fund promising treatments
|
|
Aug 10
|
Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update
|